154 related articles for article (PubMed ID: 27609715)
1. Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent.
Shafiee F; Rabbani M; Jahanian-Najafabadi A
J Microbiol Methods; 2016 Nov; 130():100-105. PubMed ID: 27609715
[TBL] [Abstract][Full Text] [Related]
2. Optimization of the Expression of DT386-BR2 Fusion Protein in
Shafiee F; Rabbani M; Jahanian-Najafabadi A
Adv Biomed Res; 2017; 6():22. PubMed ID: 28349025
[TBL] [Abstract][Full Text] [Related]
3. Expression and purification of truncated diphtheria toxin, DT386, in
Shafiee F; Rabbani M; Behdani M; Jahanian-Najafabadi A
Res Pharm Sci; 2016 Oct; 11(5):428-434. PubMed ID: 27920826
[TBL] [Abstract][Full Text] [Related]
4. Expression, purification, and cytotoxic evaluation of IL24-BR2 fusion protein.
Pourhadi M; Jamalzade F; Jahanian-Najafabadi A; Shafiee F
Res Pharm Sci; 2019 Aug; 14(4):320-328. PubMed ID: 31516508
[TBL] [Abstract][Full Text] [Related]
5. Modified DT-IL2 fusion toxin targeting uniquely IL2Ralpha expressing leukemia cell lines - Construction and characterization.
Potala S; Verma RS
J Biotechnol; 2010 Jul; 148(2-3):147-55. PubMed ID: 20580754
[TBL] [Abstract][Full Text] [Related]
6. [Construction and expression of the fusion protein DT389-hIL-13 and its cytotoxicity to glioma cell lines].
Tuo HZ; Wang JW; Wang DX; Li JM; Ouyang J; Hong T
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(12):1024-8. PubMed ID: 15312540
[TBL] [Abstract][Full Text] [Related]
7. Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies.
Williams MD; Rostovtsev A; Narla RK; Uckun FM
Protein Expr Purif; 1998 Jul; 13(2):210-21. PubMed ID: 9675065
[TBL] [Abstract][Full Text] [Related]
8. Potent in vitro antitumor activity of B-subunit of Shiga toxin conjugated to the diphtheria toxin against breast cancer.
Mohseni Z; Sedighian H; Halabian R; Amani J; Behzadi E; Imani Fooladi AA
Eur J Pharmacol; 2021 May; 899():174057. PubMed ID: 33753109
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of neovascularisation in human endothelial cells using anti NRP-1 nanobody fused to truncated form of diphtheria toxin as a novel immunotoxin.
Naderi S; Roshan R; Behdani M; Kazemi-Lomedasht F
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):230-238. PubMed ID: 33657977
[TBL] [Abstract][Full Text] [Related]
10.
Mousavi A; Sabouri A; Hassanzadeh Eskafi A; Alirahimi E; Kazemi-Lomedasht F; Ghaderi H; Behdani M
Monoclon Antib Immunodiagn Immunother; 2021 Jun; 40(3):113-117. PubMed ID: 34076502
[TBL] [Abstract][Full Text] [Related]
11. The Enhanced Cytotoxic Effects of the p28-Apoptin Chimeric Protein As A Novel Anti-Cancer Agent on Breast Cancer Cell Lines.
Noei A; Nili-Ahmadabadi A; Soleimani M
Drug Res (Stuttg); 2019 Feb; 69(3):144-150. PubMed ID: 30060264
[TBL] [Abstract][Full Text] [Related]
12. Production and Conjugation of Truncated Recombinant Diphtheria Toxin to VEGFR-2 Specific Nanobody and Evaluation of its Cytotoxic Effect on PC-3 Cell Line.
Shajari S; Farajollahi MM; Behdani M; Tarighi P
Mol Biotechnol; 2022 Nov; 64(11):1218-1226. PubMed ID: 35478310
[TBL] [Abstract][Full Text] [Related]
13. Expression, purification, characterization, and cytotoxic evaluation of the ML1-STxB fusion protein.
Yousefi MH; Afkhami H; Akbari A; Honari H
Arch Microbiol; 2023 May; 205(6):220. PubMed ID: 37148384
[TBL] [Abstract][Full Text] [Related]
14. Targeting head and neck squamous cell carcinoma using a novel fusion toxin-diphtheria toxin/HN-1.
Potala S; Verma RS
Mol Biol Rep; 2011 Feb; 38(2):1389-97. PubMed ID: 20814829
[TBL] [Abstract][Full Text] [Related]
15. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.
Frankel AE; Ramage J; Latimer A; Feely T; Delatte S; Hall P; Tagge E; Kreitman R; Willingham M
Protein Expr Purif; 1999 Jun; 16(1):190-201. PubMed ID: 10336877
[TBL] [Abstract][Full Text] [Related]
16. Expression, purification, and therapeutic implications of recombinant sFRP1.
Ghoshal A; Ghosh SS
Appl Biochem Biotechnol; 2015 Feb; 175(4):2087-103. PubMed ID: 25432334
[TBL] [Abstract][Full Text] [Related]
17. Fusion protein of interleukin 4 and diphtherial toxin with high cytotoxicity to cancer cells.
Zhang YJ; Hu XB; Li SX; Tian LP; Yang SL; Gong Y
Acta Biochim Biophys Sin (Shanghai); 2004 Jun; 36(6):437-42. PubMed ID: 15188060
[TBL] [Abstract][Full Text] [Related]
18. Expression and purification of a recombinant ELRL-MAP30 with dual-targeting anti-tumor bioactivity.
Chen WW; Zhang HR; Huang ZG; Zhou ZY; Lou QW; Jiang XY; Zhu ZH
Protein Expr Purif; 2021 Sep; 185():105893. PubMed ID: 33933613
[TBL] [Abstract][Full Text] [Related]
19. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
Urieto JO; Liu T; Black JH; Cohen KA; Hall PD; Willingham MC; Pennell LK; Hogge DE; Kreitman RJ; Frankel AE
Protein Expr Purif; 2004 Jan; 33(1):123-33. PubMed ID: 14680969
[TBL] [Abstract][Full Text] [Related]
20. Large-scale purification and characterization of recombinant fibroblast growth factor-saporin mitotoxin.
McDonald JR; Ong M; Shen C; Parandoosh Z; Sosnowski B; Bussell S; Houston LL
Protein Expr Purif; 1996 Aug; 8(1):97-108. PubMed ID: 8812840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
